FLUOCINONIDE EMULSIFIED BASE
Clinical safety rating: safe
No significant drug interactions Systemic absorption can occur with extensive use.
Fluocinonide is a corticosteroid that binds to the glucocorticoid receptor, leading to inhibition of phospholipase A2, reduction of prostaglandin and leukotriene synthesis, and suppression of inflammatory mediators. In an emulsified base, it enhances penetration and local anti-inflammatory activity.
| Metabolism | Fluocinonide is metabolized primarily in the skin and liver via hydrolysis to inactive metabolites; cytochrome P450 enzymes are not significantly involved. |
| Excretion | Fluocinonide is primarily metabolized in the liver, and its metabolites are excreted via the kidneys (approximately 60-70%) and feces (30-40%). No unchanged drug is excreted. |
| Half-life | The terminal elimination half-life of fluocinonide is approximately 1-2 hours after topical administration, reflecting rapid systemic clearance. This short half-life minimizes systemic accumulation with once- or twice-daily dosing. |
| Protein binding | Fluocinonide is approximately 96-99% bound to plasma proteins, primarily albumin and corticosteroid-binding globulin (CBG). |
| Volume of Distribution | The volume of distribution is not well-defined for fluocinonide due to minimal systemic absorption after topical use. Based on animal data, Vd is estimated at 0.1-0.3 L/kg, indicating distribution primarily into extracellular fluid and limited tissue binding. |
| Bioavailability | After topical application on intact skin, systemic bioavailability is less than 5% due to low percutaneous absorption. On inflamed or damaged skin, absorption may increase up to 10-20%. Oral bioavailability is negligible as fluocinonide is not formulated for systemic use. |
| Onset of Action | Onset of action occurs within 1-2 hours after topical application, with initial vasoconstriction and anti-inflammatory effects noted. Peak clinical improvement may require 3-7 days of regular use. |
| Duration of Action | Duration of action after a single topical application is 12-24 hours, supporting once- or twice-daily dosing. Prolonged use may lead to tachyphylaxis, reducing efficacy over time. |
| Molecular Weight | 494.5 |
Apply a thin film to affected area once to twice daily. Topical use only. Maximum duration of continuous use is 2 weeks. Total dosage should not exceed 60 g per week.
| Dosage form | CREAM |
| Renal impairment | No specific renal dose adjustment required for topical use. Systemic absorption is minimal; however, caution in severe renal impairment due to potential effects of absorbed corticosteroid. |
| Liver impairment | No specific hepatic dose adjustment required for topical use. Systemic absorption is minimal; however, caution in severe hepatic impairment due to potential effects of absorbed corticosteroid. |
| Pediatric use | Use lowest potency and smallest amount necessary. Apply a thin film to affected area once to twice daily for no longer than 2 weeks. Avoid prolonged use, occlusion, and application to large body surface area due to increased risk of systemic absorption. |
| Geriatric use | Use lowest potency and smallest amount necessary. Apply a thin film to affected area once to twice daily. Avoid prolonged use and occlusion due to thinner skin and increased risk of systemic absorption. Monitor for skin atrophy and local adverse effects. |
| 1st trimester | Generally avoided unless benefit outweighs risk; potential for cleft palate if high-dose systemic exposure. Topical use with caution not recommended. |
| 2nd trimester | May be used with caution for short duration on small areas; risk of fetal adrenal suppression with extensive use. |
| 3rd trimester | Considered safer for short-term topical use; avoid prolonged or high-potency application near term due to possible neonatal adrenal suppression. |
Clinical note
No significant drug interactions Systemic absorption can occur with extensive use.
| FDA category | Animal |
| Placental transfer | Fluocinonide undergoes placental transfer; degree depends on topical dose and application surface area. Systemic absorption from topical use is low, but with extensive or occluded use, significant transfer may occur. |
■ FDA Black Box Warning
None.
| Common Effects | Skin atrophy |
| Serious Effects |
Hypersensitivity to fluocinonide or any corticosteroidUntreated bacterial, viral, or fungal skin infectionsPerioral dermatitisAcne vulgarisRosacea
| Precautions | Topical corticosteroids may cause reversible hypothalamic-pituitary-adrenal (HPA) axis suppression with potential glucocorticosteroid insufficiency after withdrawal., Systemic absorption may produce Cushing's syndrome, hyperglycemia, and glucosuria., Use over large body surface areas, prolonged use, or occlusive dressings increase systemic absorption., Local adverse reactions include skin atrophy, striae, telangiectasias, burning, itching, irritation, dryness, folliculitis, and allergic contact dermatitis., Avoid use on face, axillae, or groin unless directed by physician., Not for ophthalmic use. |
| Food/Dietary |
Loading safety data…
| Breastfeeding |
| Apply sparingly on small areas; avoid contact with infant skin. Systemic absorption is minimal with topical use, but high-potency steroids should be used cautiously. Monitor infant for signs of adrenal suppression if prolonged use. |
| Lactation Rating | L3: Moderately Safe |
| Teratogenic Risk | Topical corticosteroids are generally considered low risk for teratogenicity when used as directed. In animal studies, high systemic doses of corticosteroids have been associated with cleft palate, intrauterine growth restriction, and increased fetal mortality. For fluocinonide, specific human data are lacking. Use during pregnancy should be limited to small areas, short durations, and lowest effective potency, especially during the first trimester. |
| Fetal Monitoring | No specific monitoring is required beyond routine prenatal care. If used extensively or for prolonged periods, monitor for maternal skin atrophy, adrenal suppression, and signs of systemic effects. Fetal growth should be assessed if high-potency corticosteroids are used over large body surface areas. |
| Fertility Effects | No reproductive toxicity studies have been conducted with fluocinonide. Effects on fertility are not expected at topical doses. Systemic corticosteroids may affect fertility in animal studies, but relevance to humans is minimal with topical use. |
| No known food interactions. |
| Clinical Pearls | Fluocinonide in an emulsified base (e.g., Vanos) is a super-high-potency corticosteroid. Apply a thin layer to affected areas only; avoid occlusion unless directed. Use limited to 2 weeks consecutively due to risk of skin atrophy and systemic absorption. Do not use on face, groin, or axillae. Monitor for HPA axis suppression with large body surface area use. |
| Patient Advice | Apply a thin layer only to affected skin; avoid healthy skin. · Do not use for more than 2 weeks unless told by your doctor. · Wash hands after application unless treating hands. · Do not cover the area with bandages or wraps unless directed. · Avoid contact with eyes, mouth, and mucous membranes. · Do not use on broken skin or infections. · Report any signs of skin thinning, burning, or infection to your doctor. · Use only as prescribed; this is a strong steroid. |